New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
12:35 EDTDGX, MMMQuest Diagnostics unit, 3M say FDA gives clearance for Simplexa test
Focus Diagnostics, a business of Quest Diagnostics (DGX), and 3M (MMM) announced that the U.S. Food and Drug Administration has provided 510(k) clearance and CLIA moderate-complexity categorization to the Simplexa Flu A/B & RSV Direct test on the 3M Integrated Cycler. The new test aids in the qualitative detection and differentiation of RNA of influenza A and B viruses and respiratory syncytial virus, common causes of respiratory illness. The Simplexa Flu A/B & RSV Direct is now available in the United States. It was CE marked for distribution in Europe in 2011.
News For DGX;MMM From The Last 14 Days
Check below for free stories on DGX;MMM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
11:23 EDTDGXQuest Diagnostics shares recommended at Maxim
Subscribe for More Information
09:28 EDTMMM3M sees foreign currency translation reducing FY sales by approx. 1%
Says currency reduced sales by 2% in Q1, which was about 1% worse than its expectation entering the year. Says sees foreign currency translation reducing FY sales by approximately 1%, a slightly bigger headwind than previously expected. Says continues to experience positive selling price changes across its businesses. Says weather negatively impacted certain channels that it serves in the U.S. in Q1, particularly in road construction and retail. For 2013-2017, says planning to invest $5B-$10B+ on acquisitions, says multi-billion dollar deals possible. Sees strong investment in R&D, CapEx in 2013-2017, says organic growth remains "paramount." Expects to add leverage of $2B-$4B on the balance sheet for CY14. Sees strong margin performance continuing. Sees FY14 CapEx $1.7B-$1.8B. Sees FY gross share repurchases $4B-$5B. Comments made on the Q1 earnings conference call.
08:58 EDTMMM3M Company sees FY14 tax rate 28%-29%
Sees free cash flow conversion 90%-100%. Says planning share repuchases of $17B-$22B over 2013-2017. Comments from slides that will be presented on the Q1 earnings conference call.
07:34 EDTMMM3M Company backs FY14 EPS view $7.30-$7.55, consensus $7.46
Subscribe for More Information
07:32 EDTMMM3M Company reports Q1 EPS $1.79, consensus $1.80
Reports Q1 revenue $7.83B, consensus $7.96B. Reports organic local-currency sales growth of 4.6%.
07:23 EDTDGXQuest Diagnostics expects to show positive revenue growth beginning in Q2
07:07 EDTDGXQuest Diagnostics sees FY14 adjusted EPS $3.95-$4.15, consensus $4.04
Subscribe for More Information
07:06 EDTDGXQuest Diagnostics reports Q1 adjusted EPS 84c, consensus 88c
Subscribe for More Information
April 23, 2014
16:54 EDTDGXQuest Diagnostics extends partnership with Steward Health Care System
Subscribe for More Information
15:35 EDTMMMNotable companies reporting before tomorrow's open
Subscribe for More Information
13:01 EDTDGXQuest Diagnostics management to meet with Jefferies
Subscribe for More Information
13:00 EDTDGXQuest Diagnostics management to meet with Oppenheimer
Meeting to be held in Chicago on April 27 hosted by Oppenheimer.
07:47 EDTMMM3M Company April weekly volatility elevated into Q1 and growth outlook
Subscribe for More Information
April 16, 2014
08:17 EDTMMM3M against proposal for shareholder actions without vote first, Reuters says
3M Company said its board opposed a proposal by shareholder James McRitchie to allow investors with a certain amount of shares to take a specific action through written consent without voting first, according to Reuters, citing a company letter to stockholders. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use